Does expression of CD24 in adenocarcinomas of the pancreas correlate with higher tumor grades?
CD24 is commonly expressed in adenocarcinomas of the pancreas, preferentially high-grade tumors and thus might be a marker of disease progression.
These results indicate that a CSF peptidomic approach may be a valuable tool both to verify target engagement and to identify other pharmacodynamic effects of the drug. Data are available via ProteomeXchange with identifier PXD003075.